We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Moberg Pharma Ab (publ) | LSE:0P48 | London | Ordinary Share | SE0003613090 | MOBERG PHARMA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 30.45 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
STOCKHOLM, Nov. 30, 2020 /PRNewswire/ -- Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has obtained a positive decision confirming that the Swedish Tax Agency shares the Company's assessment that the Company's proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, which means that the distribution will not be subject to taxation for the Company's shareholders.
The board of directors of Moberg Pharma has proposed that the extraordinary general meeting to be held tomorrow, 1 December 2020, approves to distribute all of the Company's shares in the subsidiary OncoZenge through a Lex Asea distribution with a contemplated record date in January/February 2021.
The Company now has a obtained a decision confirming that the Swedish Tax Agency shares the Company's assessment that the Company's proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act with, which means that the distribution will not be subject to taxation for Moberg Pharma's shareholders.
For additional information, please contact:
Anna Ljung
CEO
Phone: + 46 70 766 60 30
e-mail: anna.ljung@mobergpharma.se
Mark Beveridge
VP Finance
Phone: + 46 76 805 82 88
e-mail: mark.beveridge@mobergpharma.se
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/moberg-pharma/r/moberg-pharma-obtains-positive-decision-from-the-swedish-tax-agency-regarding-the-lex-asea-distribut,c3246153
The following files are available for download:
https://mb.cision.com/Main/1662/3246153/1341952.pdf | Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge |
View original content:http://www.prnewswire.com/news-releases/moberg-pharma-obtains-positive-decision-from-the-swedish-tax-agency-regarding-the-lex-asea-distribution-of-the-shares-in-oncozenge-301181582.html
SOURCE Moberg Pharma
Copyright 2020 PR Newswire
1 Year Moberg Pharma Ab (publ) Chart |
1 Month Moberg Pharma Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
